Financials data is unavailable for this security.
View more
Year on year Avecho Biotechnology Ltd 's revenues fell -58.07% from 1.13m to 473.55k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 2.34m to a larger loss of 3.44m.
Gross margin | -45.60% |
---|---|
Net profit margin | -1,026.91% |
Operating margin | -1,026.91% |
Return on assets | -71.20% |
---|---|
Return on equity | -108.69% |
Return on investment | -105.46% |
More ▼
Cash flow in AUDView more
In 2023, Avecho Biotechnology Ltd increased its cash reserves by 274.91%, or 4.04m. Cash Flow from Financing totalled 7.22m or 1,523.84% of revenues. In addition the company used 3.18m for operations while cash from investing was breakeven.
Cash flow per share | -0.0012 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.0013 |
---|---|
Tangible book value per share | 0.0013 |
More ▼
Balance sheet in AUDView more
Current ratio | 3.54 |
---|---|
Quick ratio | 3.48 |
Total debt/total equity | 0.0326 |
---|---|
Total debt/total capital | 0.0316 |
More ▼
Growth rates in AUD
SmartText is unavailable
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | 38.97 |